MAJOR ADVANCES IN NEJM: BREAST CANCER DRUGS TO TREAT PROSTATE CANCER ARE MORE EFFECTIVE THAN STANDARD THERAPIES!

May 26, 2020 /
BiovalleyBIOON /- A majorclinical trialreported that a drug that has been approved to treatbreast cancerand ovarian cancer is more effective than targeted hormone therapy in controlling cancer in certain patients with advanced prostate cancerOlapani, a drug with no side effects of chemotherapy, can treat prostate cancer's Achilles heel, the weak ability to repair damaged DNANow, it is about to be approved as the first gene-targeted therapy for prostate cancerthe precise drug, known as PARP inhibitors, specifically targeting DNA to repair genetically defective cancer cells, is more effective at stopping the growth of prostate cancer than modern targeted hormone therapy serotonin and nzalutamathe final results of the far-reaching trial, published in the prestigious New England Journal of Medicine today, bode well for Olapani's landmark prostate cancer drug approvals in the United States and Europe this yearThe study was funded byAstraZenecaimage source: Wikipediaa team from the London Cancer Institute and the Royal Marsden NHS Foundation Trust, along with colleagues from around the world from Northwestern University in Chicago, the United States, studied 387 patients with advanced prostate cancer, one or more of their 15 DNA repair genesThe researchers found that the use of Olapani in men with defective DNA repair genes could significantly delay the progression of the diseaseprostate cancer patients with BRCA1, BRCA2 or ATM genetic defects benefited most from TheOlapani treatment, with no progression of 7.4 months, compared with 3.6 months for patients taking nzalitamine and abitron 12 other pre-selected DNA-repaired genes also benefited from Orapani overall, after using Orapani, the average time before their cancer worsened was 5.8 months in men with any of the 15 DNA repair genes, compared with 3.5 months for men who used targeted hormone therapy Cancer Institute (ICR) found that Abercrombie, developed by ICR and Royal Marsden, changed the treatment of advanced prostate cancer researchers are excited about the prospect of Olapani, who has found a genetically targeted approach that may be more effective than Abiton in men whose DNA repair mutations men with BRCA1, BRCA2 or ATM genetic defects had an overall survival of 19 months after receiving Orapani treatment, while the total survival period after treatment with Nzalutamide and abitron was 15 months - although 80 percent of patients switched to Orapani after cancer progression and metastasis However, it takes longer follow-up to eventually show an improvement in survival rates the most common adverse reactions are anemia and nausea But in general, Orapani is a well-tolerated treatment that works much better for patients than chemotherapy PROfound is the first to show how important genetic testing is in prostate cancer patients It is important to determine their treatment options based on the genes of different groups of patients researchers now hope that within the next two years, Olapani could be used to treat patients with advanced prostate cancer with defective DNA repair genes next step, they will consider combining Orapani with other treatments to further improve the outcome Professor Johann de Bono, professor of experimental cancer medicine at the Institute of Cancer Research in London and
a consultant in oncology at the Royal Marsden NHS Foundation Trust and a consultant in oncology , said: "
our findings suggest that Olapani - a drug that targets cancer cells with a fatal weakness that does not harm normal healthy cells - works better than targeted hormone therapy in some patients with advanced prostate cancer." It is exciting to see that a drug that has prolonged the lives of many ovarian and breast cancer patients is now showing such obvious benefits in treating prostate cancer I can't wait to see the drug start to apply to men who can benefit Next, we'll evaluate how to combine Olapani with other treatments to help men with prostate cancer and DNA repair genetic allys live longer Johann de Bono, 59, , a patient at the Royal Marsden Hospital, said: '
initially after the diagnosis, I underwent hormone therapy, then chemotherapy Six months after the end of chemotherapy, my PSA rose rapidly and the doctor told me that my chances of living two years were very low I went to the Royal Marsden Hospital for a second opinion, and Professor Johann de Bono found that I had a genetic mutation suitable for the Orapani trial I've been on medication for almost two years There were a lot of tumors in my lymph nodes before the drug , but now I can only see one and I'm very lucky to have no side effects Professor Paul Workman, chief executive of the Institute of Cancer Research in London, said: "
is pleased to see this treatment, and we have learned how to treat the gene of the mutated gene, which can successfully treat some patients with advanced prostate cancer." The landmark findings mean that Olapani will now be the first gene-targeted drug to treat the disease The next step will be to find new ways to combine Orapani with other treatments to prevent or overcome drug resistance The study is aimed at the lethal ability to adapt and evolve cancer, and will be conducted at the Cancer Drug Discovery Center later this year (biovalleybioon.com) reference: 1, Major trial show breast cancer can beta cancer cancer Achilles heel 2) And ovarian cancer cancer drug out-performs hormone singrapy in some men
3 Johann de Bono et al.
Olaparib for Metastatic Castration-Resistant Prostate Cancer New England Journal of Medicine of Medicine (2020) DOI: 10.1056/NEJMoa1911440